<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80547">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01829347</url>
  </required_header>
  <id_info>
    <org_study_id>VTI-210</org_study_id>
    <nct_id>NCT01829347</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Alcoholic Hepatitis Who Have Failed Steroid Therapy</brief_title>
  <official_title>A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Acute Alcoholic Hepatitis (AAH) Who Have Failed Steroid Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vital Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vital Therapies, Inc.</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treatment with the ELAD System is safe and
      effective in subjects with severe acute alcoholic hepatitis who have failed steroid therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with severe acute alcoholic hepatitis (sAAH) are often treated with steroids as
      soon as their diagnosis is confirmed.  This study is to assess treatment with the ELAD
      System in subjects where the steroid treatment has failed.  ELAD treatment is done
      continuously for up to 10 days in addition to standard of care treatment.  The Control group
      (those chosen not to receive ELAD treatment) will also get standard of care treatment.
      Standard of care is defined as the usual care for diet, medications, treatment of
      complications that may arise, etc. for sAAH patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival at Day 91</measure>
    <time_frame>Study Day 1 through Study Day 91</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overall survival of subjects will be assessed from study randomization (Day 1) through Study Day 91.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the proportion of survivors at Study Days 28 and 91.</measure>
    <time_frame>Study Days 28 and 91.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Severe Acute Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>ELAD (plus Standard of Care)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELAD  is a cellular, extracorporeal, liver assist system. Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (Control)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD.EASL Guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ELAD</intervention_name>
    <description>ELAD is an extracorporeal system that runs blood(plasma) through liver cells outside the body.</description>
    <arm_group_label>ELAD (plus Standard of Care)</arm_group_label>
    <other_name>Liver assist system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care treatment</intervention_name>
    <description>Standard of care is predefined treatment for AAH complications (ascites, hepatic encephalopathy, varices, etc.)</description>
    <arm_group_label>ELAD (plus Standard of Care)</arm_group_label>
    <arm_group_label>Standard of Care (Control)</arm_group_label>
    <other_name>Usual treatment for the disease</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 ;

          -  Total bilirubin ≥ 8 mg/dL;

          -  A clinical diagnosis of acute alcoholic hepatitis (AAH), confirmed by liver biopsy;

          -  Subject must have failed steroid therapy according to Lille protocol (Lille score &gt;
             0.45) after at least 7 and not more than 9 days of steroid therapy.

        Exclusion Criteria:

          -  Platelet count &lt; 50,000/mm3;

          -  International Normalization Ratio (INR) &gt; 3.0;

          -  Evidence of infection unresponsive to antibiotics;

          -  Evidence of more than one steroid regimen during this episode of liver failure;

          -  Hospital admission for any episodes of liver decompensation within the past 2 months;

          -  On mechanical ventilation;

          -  Evidence of hemodynamic instability;

          -  Evidence of active bleeding or of major hemorrhage;

          -  Evidence of variceal bleeding within 7 days of Screening;

          -  Evidence of occlusive portal vein thrombosis, or evidence of bile duct obstruction;

          -  Evidence by physical exam, history, or laboratory evaluation of significant
             concomitant disease with expected life expectancy of less than 3 months;

          -  Chronic end-stage renal disease requiring chronic hemodialysis for more than 8 weeks
             (not classified as hepatorenal syndrome);

          -  Uncontrolled seizures;

          -  Positive serologies for viral hepatitis B or C;

          -  Pregnancy or lactation;

          -  Participation in another investigational drug, biologic, or device study within one
             month of enrollment, except for observational studies;

          -  Previous liver transplant;

          -  Previous participation in a clinical trial involving ELAD;

          -  Foreseeable eligibility for liver transplant during the 90-day study period;

          -  Has a Do Not Resuscitate or a Do Not Intubate (DNR/DNI) directive (or local
             equivalent) or any other Advanced Directive limiting Standard of Care in place;

          -  Inability to provide an address for follow-up home health visits

        And other inclusion/exclusion criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Stange, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vital Therapies, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajiv Jalan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Caballeria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis Montero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Reina Sofia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Bañares, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Gregorio Marañon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Henry</last_name>
    <phone>858-673-6840</phone>
    <phone_ext>1844</phone_ext>
    <email>ahenry@vitaltherapies.copm</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Stephens</last_name>
    <phone>858-924-1991</phone>
    <email>mstephens@vitaltherapies.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Caballeria, MD</last_name>
      <phone>+34 93 227 17 13</phone>
      <email>CABALLER@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Juan Caballeria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luís Montero, MD</last_name>
      <phone>+34 957 01 03 28</phone>
      <email>jlm14005623@gmail.com</email>
    </contact>
    <investigator>
      <last_name>José Luís Montero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Bañares, MD</last_name>
      <phone>+34 91 586 86 99</phone>
      <email>rbanares@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Rafael Bañares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>Hampstead</city>
        <state>London</state>
        <zip>NW3 2QR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melrose Browne-Morgan</last_name>
      <phone>+44 020 7794 0500</phone>
      <phone_ext>22522</phone_ext>
      <email>melrose.browne-morgan@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Nicola Childs, RN</last_name>
      <phone>+44 020 7794 0500</phone>
      <phone_ext>22522</phone_ext>
      <email>nicola.childs@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Rajiv Jalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.vitaltherapies.com</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver failure</keyword>
  <keyword>acute alcoholic hepatitis</keyword>
  <keyword>patients failing steroid therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
